TERNS PHARMACEUTICALS INC Share Price Today: Live Updates & Key Insights

TERNS PHARMACEUTICALS INC share price today is $48.52, up -1.26%. The stock opened at $48.34 against the previous close of $49.06, with an intraday high of $49.79 and low of $47.98.

TERNS PHARMACEUTICALS INC Share Price Chart

TERNS PHARMACEUTICALS INC

us-stock
To Invest in {{usstockname}}
us-stock

TERNS PHARMACEUTICALS INC Share Price Performance

$48.52 -0.0126(-1.26%) TERN at 23 Mar 2026 03:28 PM Biotechnology
Lowest Today 47.98
Highest Today 49.79
Today’s Open 48.34
Prev. Close 49.06
52 Week High 50.00
52 Week Low 1.87
Day’s Range: Low 47.98 High 49.79
52-Week Range: Low 1.87 High 50.00
1 day return -
1 Week return +5.32
1 month return +18.78
3 month return +19.22
6 month return +542.38
1 year return +1281.76
3 year return +451.76
5 year return +115.45
10 year return -

TERNS PHARMACEUTICALS INC Institutional Holdings

Soleus Capital Management, L.P. 7.47

Morgan Stanley - Brokerage Accounts 6.98

Deep Track Capital, LP 6.89

BlackRock Inc 5.10

Adage Capital Partners Gp LLC 5.10

Vanguard Group Inc 5.08

Vivo Capital, LLC 4.92

Vestal Point Capital LP 4.14

Vanguard Total Stock Mkt Idx Inv 2.94

Citadel Advisors Llc 2.91

Capitolis Liquid Global Markets LLC 2.80

Holocene Advisors, LP 2.55

Lord, Abbett & Co LLC 2.49

Orbimed Advisors, LLC 1.98

Geode Capital Management, LLC 1.93

iShares Russell 2000 ETF 1.92

Nearwater Capital Markets, Ltd 1.57

State Street Corp 1.48

Lord Abbett Growth Leaders I 1.46

Pictet Asset Manangement SA 1.45

HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 1.39

COMMODORE CAPITAL LP 1.36

Woodline Partners LP 1.27

Franklin Biotechnology Discv A(acc)USD 1.24

HBM Healthcare Investments AG Ord 1.06

Candriam Eqs L Biotech C USD Cap 1.02

Fidelity Select Biotechnology 1.02

American Funds SMALLCAP World A 0.97

Lord Abbett & Co. Growth Equity- SA 0.91

Lord Abbett Growth Leaders SMA 0.91

Pictet-Biotech P USD 0.88

Vanguard Institutional Extnd Mkt Idx Tr 0.86

Fidelity Small Cap Index 0.77

Franklin Biotechnology Discovery A 0.71

Lord Abbett Developing Growth A 0.70

iShares Russell 2000 Value ETF 0.68

iShares Biotechnology ETF 0.62

Belfius Equities Cure C Cap 0.58

Nuveen Quant Small Cap Equity R6 0.51

Columbia Small Cap Growth 0.48

TERNS PHARMACEUTICALS INC Market Status

Strong Buy: 5

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

TERNS PHARMACEUTICALS INC Fundamentals

Market Cap 5268.69 M

PB Ratio 18.6048

PE Ratio 0.0

Enterprise Value 4990.40 M

Total Assets 363.93 M

Volume 4863348

TERNS PHARMACEUTICALS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:1000000 1.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-881000 -0.9M, FY22:null 0.0M, FY21:1000000 1.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-90210000 -90.2M, FY22:-60345000 -60.3M, FY21:-50158000 -50.2M, FY20:-40571000 -40.6M, FY19:-68819000 -68.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-108000 -0.1M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-240000 -0.2M

Quarterly Net worth Q3/2025:-24635000 -24.6M, Q2/2025:-24093000 -24.1M, Q1/2025:-23908000 -23.9M, Q3/2024:-21945000 -21.9M, Q2/2024:-22736000 -22.7M

About TERNS PHARMACEUTICALS INC & investment objective

Company Information Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Organisation Biotechnology

Employees 59

Industry Biotechnology

CEO Ms. Amy L. Burroughs M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

TERNS PHARMACEUTICALS INC FAQs

What is the share price of TERNS PHARMACEUTICALS INC today?

The current share price of TERNS PHARMACEUTICALS INC is $48.52.

Can I buy TERNS PHARMACEUTICALS INC shares in India?

Yes, Indian investors can buy TERNS PHARMACEUTICALS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy TERNS PHARMACEUTICALS INC shares in India?

You can easily invest in TERNS PHARMACEUTICALS INC shares from India by:

Can I buy fractional shares of TERNS PHARMACEUTICALS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of TERNS PHARMACEUTICALS INC?

TERNS PHARMACEUTICALS INC has a market cap of $5268.69 M.

In which sector does TERNS PHARMACEUTICALS INC belong?

TERNS PHARMACEUTICALS INC operates in the Biotechnology sector.

What documents are required to invest in TERNS PHARMACEUTICALS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of TERNS PHARMACEUTICALS INC?

The PE ratio of TERNS PHARMACEUTICALS INC is N/A and the PB ratio is 18.60.